JP2019518439A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518439A5
JP2019518439A5 JP2018557329A JP2018557329A JP2019518439A5 JP 2019518439 A5 JP2019518439 A5 JP 2019518439A5 JP 2018557329 A JP2018557329 A JP 2018557329A JP 2018557329 A JP2018557329 A JP 2018557329A JP 2019518439 A5 JP2019518439 A5 JP 2019518439A5
Authority
JP
Japan
Prior art keywords
nucleic acid
meg3
cardiac
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6928001B2 (ja
JP2019518439A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059984 external-priority patent/WO2017191021A1/en
Publication of JP2019518439A publication Critical patent/JP2019518439A/ja
Publication of JP2019518439A5 publication Critical patent/JP2019518439A5/ja
Application granted granted Critical
Publication of JP6928001B2 publication Critical patent/JP6928001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557329A 2016-05-02 2017-04-26 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３ Active JP6928001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167961.8 2016-05-02
EP16167961 2016-05-02
PCT/EP2017/059984 WO2017191021A1 (en) 2016-05-02 2017-04-26 The incrna meg3 for therapy and diagnosis of cardiac remodelling

Publications (3)

Publication Number Publication Date
JP2019518439A JP2019518439A (ja) 2019-07-04
JP2019518439A5 true JP2019518439A5 (enExample) 2020-05-07
JP6928001B2 JP6928001B2 (ja) 2021-09-01

Family

ID=56026647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557329A Active JP6928001B2 (ja) 2016-05-02 2017-04-26 心臓リモデリングの治療及び診断のためのｌｎｃＲＮＡ Ｍｅｇ３

Country Status (4)

Country Link
US (1) US11186838B2 (enExample)
EP (1) EP3452593B1 (enExample)
JP (1) JP6928001B2 (enExample)
WO (1) WO2017191021A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102271A1 (en) * 2018-06-01 2019-12-05 Children's National Medical Center Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
WO2024003205A1 (en) * 2022-06-30 2024-01-04 Medizinische Hochschule Hannover Long non-coding rnas as target for treating fibrosis and cancer
CN116179545B (zh) * 2022-09-09 2025-10-31 上海工程技术大学 LncRNA Gm20257在制备防治病理性心肌肥厚药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease
WO2007097741A1 (en) * 2006-02-17 2007-08-30 The Trustees Of Columbia University In The City Of New York Method of diagnosing intrauterine growth restriction
US20120283130A1 (en) * 2010-01-15 2012-11-08 Shinya Yamanaka Method for screening induced pluripotent stem cells
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs

Similar Documents

Publication Publication Date Title
JP2017514813A5 (enExample)
US11981895B2 (en) Hippo and dystrophin complex signaling in cardiomyocyte renewal
JP6805304B2 (ja) 心肥大の治療および診断のためのｌｎｃＲＮＡ
Zhang et al. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes
Sangaralingham et al. Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen
JP2002501366A (ja) 心筋不全の診断と治療
Meloche et al. miRNAs in PAH: biomarker, therapeutic target or both?
JP2018518147A5 (enExample)
JP2019518439A5 (enExample)
JP2015504299A5 (enExample)
JP2020502498A5 (enExample)
US11761966B2 (en) Nourin gene-based RNA molecular network: novel early diagnostic and prognostic biomarkers for coronary artery disease, unstable angina, STEMI/NSTEMI and heart failure
CN112691193B (zh) 用于治疗扩张型心肌病的药物及筛选方法及用途
Zhao et al. Leveraging extracellular non-coding RNAs to diagnose and treat heart diseases
KR20150131555A (ko) 근육노화 진단 및 치료를 위한 마이크로rna-136
WO2014195693A1 (en) Prevention and treatment of atrial fibrillation
Chi et al. Nuclear factor 45 of tongue sole (Cynoglossus semilaevis): Evidence for functional differentiation between two isoforms in immune defense against viral and bacterial pathogens
Wang et al. Up-regulation of CXC chemokine receptor 4 expression in chronic atrial fibrillation patients with mitral valve disease may be attenuated by renin–angiotensin system blockers
Gill et al. MicroRNAs and Cardiovascular Disease: Small Signals and Big Opportunities!
Thomas et al. Epigenetics: Its Role in Aging, Diseases and Biological Age Estimation
박혜련 et al. Early Effect of (-)-epigallocatechin-3-gallate (EGCG) on Phosphorylation of Akt
Qin et al. MicroRNA-214 Inhibits Cardiac Remodeling in Mouse Models of Cardiac Pressure Overload
Moles et al. The Relationship Between Brain–Heart Autonomic Signaling and Aging: A Gender-Specific Longitudinal Perspective from the Baltimore Longitudinal Study on Aging
Araújo et al. Application of antisense oligomers based approaches to control candidiasis
Bednarek The role of telomeres an telomerase during zebrafish heart regeneration